To ask the Secretary of State for Health and Social Care, what steps NICE is taking to (a) value the benefits of medicines through the introduction of modifiers into their decision making framework, (b) improve the way uncertainty of evidence is managed in appraisals and (c) align their discount rate with the latest guidance in the Treasury Green book.
14 September 2020
We are informed by the National Institute for Health and Care Excellence (NICE) that its methods review is proceeding apace, and NICE is being ambitious in the scope and breadth of the review.
This methods review includes consideration of factors that may affect decision-making (‘modifiers’), uncertainty and the discount rate.
It is too soon for NICE to comment on the potential outcomes and any changes to its methods that may be proposed.
NICE will continue to welcome contributions from all stakeholders and there will be a public consultation on the case for change commencing in autumn this year. However, it is too soon to comment on the potential outcomes and any changes to its methods that may be proposed.